Attention Deficit Hyperactivity Disorder (ADHD) - Market Insights, Epidemiology and Market Forecast 2027

Attention Deficit Hyperactivity Disorder (ADHD) - Market Insights, Epidemiology and Market Forecast 2027

  • Pages: 120
  • Geography: Global
  • Delivery Timeline: 5 Business Days
  • Publication: Aug, 2018
  • SKU:
  • Single User License
    (20% Off)
    $6,250.00
  • Site License
    (30% Off)
    $12,500.00
  • Global License
    (40% Off)
    $18,750.00
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

DelveInsight’s ‘Attention Deficit Hyperactivity Disorder (ADHD) - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Attention Deficit Hyperactivity Disorder in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Attention Deficit Hyperactivity Disorder from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States

  • EU5 (Germany, France, Italy, Spain and the United Kingdom)

  • Japan

Study Period: 2016-2027
Attention Deficit Hyperactivity Disorder - Disease Understanding and Treatment Algorithm
According to American Psychiatric Association, ADHD is a brain/neurodevelopmental/neurobehavioral disorder and is one of the most common mental disorders affecting children. The disease also affects many adults. Symptoms of ADHD include inattention (not being able to keep focus), hyperactivity (excess movement that is not fitting to the setting) and impulsivity (hasty acts that occur in the moment without thought).
The DelveInsight Attention Deficit Hyperactivity Disorder market report gives the thorough understanding of the Attention Deficit Hyperactivity Disorder by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Attention Deficit Hyperactivity Disorder in the US, Europe, and Japan.

Attention Deficit Hyperactivity Disorder Epidemiology
The Attention Deficit Hyperactivity Disorder epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as Prevalent Cases, Age Specific Prevalence, and Diagnosed and Treatable population] scenario of Attention Deficit Hyperactivity Disorder in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to National Institute of Mental Health, the prevalence of children ever diagnosed with ADHD increased by 42% between 2003 (7.8%) and 2011 (11.0%). As per National Comorbidity Survey–Adolescent Supplement (NCS-A), the lifetime prevalence of ADHD among U.S. adolescents aged 13 to 18 years was found to be 8.7%.

Attention Deficit Hyperactivity Disorder Drug Chapters
This segment of the Attention Deficit Hyperactivity Disorder report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
While there is no cure for ADHD, currently available treatments can help reduce symptoms and improve functioning. Treatments include medications, psychotherapy, education or training, or a combination of treatments. Stimulant medications commonly prescribed for attention deficit disorder include methylphenidate (Ritalin, Concerta, Metadate, Methylin) and certain amphetamines (Dexedrine, Adderall etc.). Other newer drugs approved for the treatment of attention deficit disorder include Strattera (atomoxetine, a selective norepinephrine reuptake inhibitor) and Vyvanse (lisdexamfetamine dimesylate).

Attention Deficit Hyperactivity Disorder Market Outlook
The Attention Deficit Hyperactivity Disorder market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. 
Many players such as Sunovion, Orient Pharma, Shire and many more are involved in developing therapies for Attention Deficit Hyperactivity Disorder. Launch of emerging therapies such as Dasotraline (Sunovion), ORADUR-Methylphenidate (Orient Pharma), SHP465 (Shire) etc. are expected to significantly change the treatment landscape in of ADHD in the upcoming years.


Attention Deficit Hyperactivity Disorder Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Attention Deficit Hyperactivity Disorder Report Insights

  • Patient Population

  • Therapeutic Approaches

  • Pipeline Analysis

  • Market Size and Trends

  • Market Opportunities

  • Impact of upcoming Therapies

Attention Deficit Hyperactivity Disorder Report Key Strengths

  • 10 Years Forecast

  • 7MM Coverage 

  • Epidemiology Segmentation

  • Sub-type Segmentation

  • Key Cross Competition 

  • Highly Analyzed Market

  • Drugs Uptake

Attention Deficit Hyperactivity Disorder Report Assessment

  • Current Treatment Practices

  • Unmet Needs

  • Pipeline Product Profiles

  • Market Attractiveness

  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Attention Deficit Hyperactivity Disorder market

  • Organize sales and marketing efforts by identifying the best opportunities for Attention Deficit Hyperactivity Disorder market

  • To understand the future market competition in the Attention Deficit Hyperactivity Disorder market.

1. Report Introduction
2. Attention Deficit Hyperactivity Disorder Market Overview at a Glance
2.1. 7 Major Market Size of Attention Deficit Hyperactivity Disorder in 2017
2.2. 7 Major Market Size of Attention Deficit Hyperactivity Disorder in 2027
3. Disease Background and Overview: Attention Deficit Hyperactivity Disorder 
3.1. Introduction
3.2. Causes
3.3. Pathophysiology
3.4. Symptoms
3.5. Risk Factor
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Assumptions and Caveats
4.2. 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
4.3. Age specific prevalence of Attention Deficit Hyperactivity Disorder 
4.4. Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder
5. Attention Deficit Hyperactivity Disorder: Country- Wise Epidemiology
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
5.1.3. Age specific prevalence of Attention Deficit Hyperactivity Disorder
5.1.4. Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder
5.2. EU-5
5.2.1. Assumptions and Rationale
5.2.2. Germany
5.2.2.1. Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
5.2.2.2. Age specific prevalence of Attention Deficit Hyperactivity Disorder 
5.2.2.3. Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder
5.2.3. France
5.2.3.1. Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
5.2.3.2. Age specific prevalence of Attention Deficit Hyperactivity Disorder 
5.2.3.3. Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder
5.2.4. Italy
5.2.4.1. Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
5.2.4.2. Age specific prevalence of Attention Deficit Hyperactivity Disorder 
5.2.4.3. Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder
5.2.5. Spain
5.2.5.1. Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
5.2.5.2. Age specific prevalence of Attention Deficit Hyperactivity Disorder
5.2.5.3. Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder
5.2.6. United Kingdom
5.2.6.1. Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
5.2.6.2. Age specific prevalence of Attention Deficit Hyperactivity Disorder
5.2.6.3. Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder
5.3. Japan
5.3.1. Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
5.3.2. Age specific prevalence of Attention Deficit Hyperactivity Disorder 
5.3.3. Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder
6. Treatments & Medical Practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Marketed drugs
7.1. ADDERALL XR: Shire
7.1.1. Product Description
7.1.2. Mechanism of action
7.1.3. Regulatory milestones
7.1.4. Other Development Activities
7.1.5. Safety and Efficacy
7.1.6. Advantages and Disadvantages
7.1.7. Product Profile
7.2. Strattera: Eli Lilly
7.2.1. Product Description
7.2.2. Mechanism of action
7.2.3. Regulatory milestones
7.2.4. Other Development Activities
7.2.5. Safety and Efficacy
7.2.6. Advantages and Disadvantages
7.2.7. Product Profile
7.3. Dexmethylphenidate Hcl: Novartis
7.3.1. Product Description
7.3.2. Mechanism of action
7.3.3. Regulatory milestones
7.3.4. Other Development Activities
7.3.5. Safety and Efficacy
7.3.6. Advantages and Disadvantages
7.3.7. Product Profile
7.4. Ritalin: Novartis
7.4.1. Product Description
7.4.2. Mechanism of action
7.4.3. Regulatory milestones
7.4.4. Other Development Activities
7.4.5. Safety and Efficacy
7.4.6. Advantages and Disadvantages
7.4.7. Product Profile
To be continued in report…
8. Emerging Therapies
8.1. Key Cross Competition
8.2. Dasotraline: Sunovion
8.2.1. Regulatory Milestones
8.2.2. Clinical Development
8.2.3. Product Profile
8.2.4. Clinical Pipeline Activity
8.2.4.1. Ongoing Trials Information
8.2.4.2. Clinical Trial by Phase
8.3. ORADUR-Methylphenidate : Orient Pharma 
8.3.1. Regulatory Milestones
8.3.2. Clinical Development
8.3.3. Product Profile
8.3.4. Clinical Pipeline Activity
8.3.4.1. Ongoing Trials Information
8.3.4.2. Clinical Trial by Phase
8.4. SHP465: Shire
8.4.1. Regulatory Milestones
8.4.2. Clinical Development
8.4.3. Product Profile
8.4.4. Clinical Pipeline Activity
8.4.4.1. Ongoing Trials Information
8.4.4.2. Clinical Trial by Phase
To be continued in report…
9. Attention Deficit Hyperactivity Disorder Market Size
9.1. Key Findings
9.2. Total 7MM Attention Deficit Hyperactivity Disorder Market Analysis 
9.2.1. Overview of Total Attention Deficit Hyperactivity Disorder Market 
9.2.2.  Market size of Attention Deficit Hyperactivity Disorder by 7MM (2016-2027)
10. 7MM Attention Deficit Hyperactivity Disorder: Country-Wise Market Analysis
10.1. United States Market Size
10.1.1. Total Market Size of Attention Deficit Hyperactivity Disorder
10.1.2. Market Size of Attention Deficit Hyperactivity Disorder by Therapies
10.2. Germany Market Size
10.2.1. Total Market Size of Attention Deficit Hyperactivity Disorder
10.2.2. Market Size of Attention Deficit Hyperactivity Disorder by Therapies
10.3. France Market Size
10.3.1. Total Market Size of Attention Deficit Hyperactivity Disorder
10.3.2. Market Size of Attention Deficit Hyperactivity Disorder by Therapies
10.4. United Kingdom Market Size
10.4.1. Total Market Size of Attention Deficit Hyperactivity Disorder
10.4.2. Market Size of Attention Deficit Hyperactivity Disorder by Therapies
10.5. Spain Market Size
10.5.1. Total Market Size of Attention Deficit Hyperactivity Disorder
10.5.2. Market Size of Attention Deficit Hyperactivity Disorder by Therapies
10.6. Italy Market Size
10.6.1. Total Market Size of Attention Deficit Hyperactivity Disorder
10.6.2. Market Size of Attention Deficit Hyperactivity Disorder by Therapies
10.7. Japan Market Size
10.7.1. Total Market Size of Attention Deficit Hyperactivity Disorder
10.7.2. Market Size of Attention Deficit Hyperactivity Disorder by Therapies
11. Report Methodology
11.1. Sources Used
12. DelveInsight Capabilities
13. Disclaimer
14. About DelveInsight

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Table 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 4 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 5 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Table 6 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 7 Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 8 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 9 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 10 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Table 11 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 12 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 13 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Table 14 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 15 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 16 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Table 18 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 19 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 20 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Table 21 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 22 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 23 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Table 24 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 25 Age specific prevalence of Attention Deficit Hyperactivity Disorder (2016-2027)
Table 26 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Table 27 Dasotraline, Clinical Trials by Recruitment status, 2018
Table 28 Dasotraline, Clinical Trials by Zone, 2018
Table 29 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Table 30 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Table 31 SHP465,Clinical Trials by Recruitment status, 2018
Table 32 SHP465,Clinical Trials by Zone, 2018
Table 39 Total 7 Major Market Size in USD, Million (2016-2027)
Table 40 Region wise Market Size in USD, Million (2016-2027)
Table 41 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 42 United States Market Size in USD, Million (2016-2027)
Table 43 United States Market Size by Therapy in USD, Million (2016-2027)
Table 44 Germany Market Size in USD, Million (2016-2027)
Table 45 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 46 France Market Size in USD, Million (2016-2027)
Table 47 France Market Size by Therapy in USD, Million (2016-2027)
Table 48 Italy Market Size in USD, Million (2016-2027)
Table 49 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 50 Spain Market Size in USD, Million (2016-2027)
Table 51 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 52 United Kingdom Market Size in USD, Million (2016-2027)
Table 53 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 54 Japan Market Size in USD, Million (2016-2027)
Table 55 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 2 7MM Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 4 Prevalent cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 5 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 6 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the US (2016-2027)
Figure 7 Prevalent cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 8 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 9 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Germany (2016-2027)
Figure 10 Prevalent cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 11 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 12 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in France (2016-2027)
Figure 13 Prevalent cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 14 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 15 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Italy (2016-2027)
Figure 16 Prevalent cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 17 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 18 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Spain (2016-2027)
Figure 19 Prevalent cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 20 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 21 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in the UK (2016-2027)
Figure 22 Prevalent cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 23 Age specific prevalence  of Attention Deficit Hyperactivity Disorder (2016-2027)
Figure 24 Diagnosed and Treatable cases of Attention Deficit Hyperactivity Disorder in Japan (2016-2027)
Figure 25 Dasotraline, Clinical Trials by Recruitment status, 2018
Figure 26 Dasotraline, Clinical Trials by Zone, 2018
Figure 27 ORADUR-Methylphenidate, Clinical Trials by Recruitment status, 2018
Figure 28 ORADUR-Methylphenidate,Clinical Trials by Zone, 2018
Figure 29 SHP465, Clinical Trials by Recruitment status, 2018
Figure 30 SHP465,Clinical Trials by Zone, 2018
Figure 37 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 38 Region wise Market Size in USD, Million (2016-2027)
Figure 39 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 40 United States Market Size in USD, Million (2016-2027)
Figure 41 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Germany Market Size in USD, Million (2016-2027)
Figure 43 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 44 France Market Size in USD, Million (2016-2027)
Figure 45 France Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Italy Market Size in USD, Million (2016-2027)
Figure 47 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Spain Market Size in USD, Million (2016-2027)
Figure 49 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 50 United Kingdom Market Size in USD, Million (2016-2027)
Figure 51 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 52 Japan Market Size in USD, Million (2016-2027)
Figure 53 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Key Companies
Speak to Analyst
Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Specific Filed of Interest*  
X

Speak to Analyst

+1(919)321-6187

Related Reports

Contact Us

Phone

India: +91-11-45689769, +91-9650213330

Email

info@delveinsight.com

Address

New Delhi-110075, India

Address

304 S. Jones Blvd #2432, Las Vegas NV 89107

Phone

Outside India: +1(919)321-6187

Latest Tweets

Copyright © 2018 Delveinsight.